Also in adult patients, tumor mutations, such as in EGFR, BRCA1/BRCA2, and SMAD4 genes, decrease engraftment rates in adenocarcinoma, breast cancer, and pancreatic cancer, respectively [14, 15, 18]. This evidence concerns the gene BRCA1 and familial pancreatic carcinoma.